US 11,938,147 B2
Treatment of neurodegenerative disease with sodium chlorite
Vernon A. Norviel, San Diego, CA (US); and Michael S. McGrath, Meadow Vista, CA (US)
Assigned to NEUVIVO, INC., Los Altos, CA (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by Neuvivo, Inc., Palo Alto, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Aug. 30, 2022, as Appl. No. 17/823,489.
Application 17/823,489 is a continuation of application No. 15/772,317, abandoned, previously published as PCT/US2016/059915, filed on Nov. 1, 2016.
Claims priority of provisional application 62/249,846, filed on Nov. 2, 2015.
Prior Publication US 2023/0181629 A1, Jun. 15, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/20 (2006.01); A61P 25/28 (2006.01)
CPC A61K 33/20 (2013.01) [A61P 25/28 (2018.01)] 14 Claims
 
1. A method of treating a dementia in a subject in need thereof, the method comprising:
a) determining that the subject has a plasma level of C-reactive protein that is at least 1125 ng/mL; and
b) based on the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL, administering to the subject an amount of sodium chlorite that is therapeutically-effective for the dementia,
wherein the subject is under age 65.